Cystatin C is a sensitive marker for detecting a reduced glomerular filtration rate when assessing chronic kidney disease in patients with rheumatoid arthritis and secondary amyloidosis

Sato, H.; Kuroda, T.; Tanabe, N.; Ajiro, J.; Wada, Y.; Murakami, S.; Sakatsume, M.; Nakano, M.; Gejyo, F.

doi:10.1080/03009740903042402

Cited by 4 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although this study included only patients with serum Cr concentrations within the normal range, the mean eGFR indicated stage 3 CKD and a moderate reduction in the GFR (30-59 mL/min/1.73 m 2 ). This reduction likely results from decreased muscle mass, as patients with RA are generally hypoactive, and serum Cr levels correlate with muscle mass (20). Although the accuracy of the eGFR as an indicator of kidney function has not been validated in patients with low muscle mass, such as those with RA, serum FGF23 did not appear to be related to serum phosphate, calcium, 25(OH)D, or intact PTH in this study, suggesting that FGF23 is unrelated to the kidney function.…”

Section: Discussionmentioning

confidence: 99%

Serum Fibroblast Growth Factor 23 (FGF23) in Patients with Rheumatoid Arthritis

et al. 2016

View full text Add to dashboard Cite

Objective Rheumatoid arthritis (RA) is a chronic inflammatory disease accompanied by periarticular and systemic osteoporosis. Fibroblast growth factor 23 (FGF23), which is mainly produced by osteocytes, circulates to the kidneys and regulates bone metabolism. We herein assessed serum FGF23 and its relationship to inflammation and osteoporosis in patients with RA. Methods Sixty-one patients with RA were included. Serum concentrations of FGF23 were determined using a sandwich enzyme-linked immunosorbent assay. Results The mean (± standard deviation) serum FGF23 concentration was 34.9±9.2 (range, 21.0-61.0) pg/ mL. The serum FGF23 level was significantly and positively correlated with the erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) levels, disease activity score-28 based on the ESR (DAS-28 ESR) and DAS-28 CRP (r=0.261, p=0.044, r=0.280, p=0.029, r=0.409, p=0.001 and r=0.421, p=0.001, respectively). The serum matrix metalloproteinase-3 level was also significantly and positively correlated with the serum FGF23 level (r=0.331, p=0.015). Concentrations of type I collagen cross-linked N-telopeptide in the serum was significantly correlated with the serum FGF23 level (r=0.272, p=0.034). Neither the bone mineral density in the femoral neck nor lumbar was significantly correlated with the serum FGF23 level. Serum phosphate, calcium, 25-hydroxy vitamin D, and intact parathyroid hormone were not related to the serum FGF23 level. Conclusion In patients with RA, serum FGF23 is correlated with inflammation, the disease activity of RA, and bone absorption markers. Serum FGF23 may be associated with abnormal bone absorption related to RA inflammation. Further studies are necessary to clarify the mechanism underlying this association.

show abstract

Section: Discussionmentioning

confidence: 99%

Serum Fibroblast Growth Factor 23 (FGF23) in Patients with Rheumatoid Arthritis

et al. 2016

View full text Add to dashboard Cite

show abstract

“…In AL amyloidosis, approximately 70% of patients present with proteinuria and two thirds are in the nephrotic range, whereas elevated creatinine is noted in one half of the patients [39,41]. Serum cystatin C has also been evaluated as an early indicator of impaired GFR in patients with amyloidosis, in particular AA type [42,43]. The available evidence suggests that cystatin C can identify a reduced GFR more accurately than serum creatinine-eGFR [42], and that it could be used as an early marker for detecting renal failure related to AA amyloidosis in specific categories at risk [43].…”

Section: Use Of Biomarkers For Early Diagnosismentioning

confidence: 99%

“…Serum cystatin C has also been evaluated as an early indicator of impaired GFR in patients with amyloidosis, in particular AA type [42,43]. The available evidence suggests that cystatin C can identify a reduced GFR more accurately than serum creatinine-eGFR [42], and that it could be used as an early marker for detecting renal failure related to AA amyloidosis in specific categories at risk [43]. Renal insufficiency and tubular dysfunction due to amyloid deposits develop at later stages, with the exception of forms such as AApoAI and ALect2, in which tubulo-interstitial damage predominates from early phases [16,44].…”

Section: Use Of Biomarkers For Early Diagnosismentioning

confidence: 99%

Biochemical markers in early diagnosis and management of systemic amyloidoses

Lavatelli

Albertini

Fonzo

et al. 2014

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

Systemic amyloid diseases are characterized by widespread protein deposition as amyloid fibrils. Precise diagnostic framing is the prerequisite for a correct management of patients. This complex process is achieved through a series of steps, which include detection of the tissue amyloid deposits, identification of the amyloid type, demonstration of the amyloidogenic precursor, and evaluation of organ dysfunction/damage. Laboratory medicine plays a central role in the diagnosis and management of systemic amyloidoses, through the quantification of the amyloidogenic precursor and evaluation of end-organ damage using biomarkers.

show abstract

“…The evaluation of clinical data for lung cancer patients was approved by the institutional ethics committee of University of Tsukuba Hospital. (8,9) where BSA indicates body surface area (m 2 ); Ht, height (cm); Wt, body weight (kg); UCr, urine creatinine concentration (mg/ dl) (using the enzymatic method); Uvol, 24 h urine volume (ml/day); SCr, serum creatinine concentration (mg/dl) (using the enzymatic method); and A, age (years). We added 0.2 to a SCr value measured using an enzymatic peroxidaseantiperoxidase method in order to render it equivalent to the SCr value measured using the Jaffē method (10).…”

Section: Patientsmentioning

confidence: 99%

Age-dependent decline in renal function in patients with lung cancer

et al. 2012

View full text Add to dashboard Cite

Abstract. The aim of this study was to clarify the effect of aging on renal function. Serum creatinine (SCr), blood urea nitrogen (BUN) and 24-h creatinine clearance (measuredCrCl) were examined in lung cancer patients and the measured-CrCl were compared with CrCl estimates by employing two commonly used equations. In total, 787 lung cancer patients who were diagnosed between 2001 and 2010 were retrospectively analyzed. SCr and urine creatinine, BUN and measured-CrCl were evaluated prior to treatment. The Cockcroft-Gault (CG) and modification of diet in renal disease (MDRD) formulae were also used to estimate CrCl. SCr, BUN and measured-CrCl showed a significant decline in the elderly. In the 787 lung cancer patients, a significant correlation coefficient was found between measured-CrCl and age. However, in patients aged 80 years or older, no significant correlation coefficient was found between measured-CrCl and age. In the comparison between the measured CrCl and the CrCls estimated by the two formulae, the CG-CrCl levels were lower than those of the measured-CrCl, whereas the MDRDCrCl levels were higher. Age is a crucial factor influencing renal function in patients with lung cancer. Particularly in the elderly, a decline in CrCl and greater individual variability in CrCl, as well as discrepancies in measured-CrCl and estimated CrCls are significant factors.

show abstract

Cystatin C is a sensitive marker for detecting a reduced glomerular filtration rate when assessing chronic kidney disease in patients with rheumatoid arthritis and secondary amyloidosis

Cited by 4 publications

References 0 publications

Serum Fibroblast Growth Factor 23 (FGF23) in Patients with Rheumatoid Arthritis

Serum Fibroblast Growth Factor 23 (FGF23) in Patients with Rheumatoid Arthritis

Biochemical markers in early diagnosis and management of systemic amyloidoses

Age-dependent decline in renal function in patients with lung cancer

Contact Info

Product

Resources

About